Enliven Therapeutics, Inc. (ELVN) — Institutional Holders, Q2 2026 (page 3)

214 institutional investment managers reported a ELVN position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $4.1B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 201 to 214. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

ELVN 13F holders ranked 201–214 of 214

Institutional investors reporting a position in Enliven Therapeutics, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
GROUP ONE TRADING, L.P.#201 · 35 sh$1.8KNew
SBI Securities , Ltd.#202 · 32 sh$1.6K+28.0%
Institute for Wealth Management#203 · 30 sh$1.5KNew
Parkside Financial Bank#204 · 30 sh$1.5K+100.0%
PNC FINANCIAL SERVICES GROUP#205 · 22 sh$1.1K0.0%
Covestor Ltd#206 · 15 sh$1.0K+150.0%
Parallel Advisors#207 · 17 sh$863.00New
NATIONAL BANK OF CANADA#208 · 7 sh$355.00New
FIFTH THIRD BANCORP#209 · 4 sh$226.00New
EverSource Wealth Advisors#210 · 3 sh$153.00-100.0%
Smartleaf Asset Management#211 · 1 sh$51.000.0%
Clearstead Advisors#212 · 1 sh$51.00New
NOMURA ASSET MANAGEMENT LTD#213 · 0 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#214 · 53,315 sh—+67.1%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.